Herceptin - $1.66 billion


Company: Genentech
2011 sales: $1.66 billion
Developer: Genentech
FDA approvals: Metastatic HER2-positive breast cancer, 1998; adjuvant in early-stage HER2-positive breast cancer, 2006; additional adjuvant approvals, 2008; HER2-positive gastric or gastroesophageal junction cancer

Herceptin is only 14 years old, and it already has a legacy. It was the first targeted cancer drug, aimed at patients whose tumors have specific genetic characteristics. In this case, the appropriate patients have tumors that over-express the HER2 gene. When Herceptin launched, personalized medicine was officially under way.

Since then, other targeted drugs have hit the market, including epidermal growth factor receptor inhibitors such as AstraZeneca's ($AZN) Iressa, Amgen's ($AMGN) Vectibix, and Bristol-Myers Squibb's ($BMY) Erbitux (No. 7 on our list). So far, none has surpassed Herceptin, sales-wise. As of 2008, more than 420,000 women had been treated with Herceptin worldwide. And with the discovery that HER2 is key in other cancers, Herceptin's use may only grow; in late 2010, it won FDA approval for gastric cancers over-expressing HER2.

Herceptin - $1.66 billion

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.